Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0CE0O
|
|||
| Former ID |
DIB004718
|
|||
| Drug Name |
Alisporivir
|
|||
| Synonyms |
DEB-025; Debio-025; HCV infection therapy, Debiopharm/Novartis; HIV infection therapy, Debiopharm
Click to Show/Hide
|
|||
| Drug Type |
Protein/peptide drug
|
|||
| Indication | Duchenne dystrophy [ICD-11: 8C70; ICD-10: G71.0] | Phase 3 | [1] | |
| Company |
Novartis pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL
|
||
| Canonical SMILES |
CCC1C(=O)N(C(C(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)C(C)C)CC)C)C
|
|||
| CAS Number |
CAS 254435-95-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Calcium signal-modulating cyclophilin ligand (CAML) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02465203) 3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study. | |||
| REF 2 | DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One. 2010 Oct 27;5(10):e13687. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.